Dec 11, 2025
Nvidia Has ‘Capabilities No Rival Can Replicate:’ Analyst

Nvidia Corp (NASDAQ:NVDA) attracted renewed attention from Wall Street after fresh insights from a recent investor meeting highlighted its continued lead in artificial intelligence computing and strong multi-year demand visibility. BofA Securities analyst Vivek Arya maintained a Buy rating on…

Dec 11, 2025
Nvidia Has ‘Capabilities No Rival Can Replicate:’ Analyst

Nvidia Corp (NASDAQ:NVDA) attracted renewed attention from Wall Street after fresh insights from a recent investor meeting highlighted its continued lead in artificial intelligence computing and strong multi-year demand visibility. BofA Securities analyst Vivek Arya maintained a Buy rating on…

Dec 11, 2025
PayPal’s Core Checkout Loses Steam—The Market Notices

PayPal Holdings, Inc. (NASDAQ:PYPL) shares were steady Thursday as investors weighed ongoing softness in consumer spending across the platform. The company continues to grapple with sluggish momentum in its core checkout business, raising fresh questions about the pace of its…

Dec 11, 2025
Natera New Test Data Could Change How Doctors Manage Breast Cancer

Natera Inc. (NASDAQ:NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer Symposium (SABCS). These first data, generated from a U.S. biomarker cohort of 420…

Dec 11, 2025
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). PWS is a rare genetic disorder characterized by muscle weakness and…

Dec 11, 2025
PayPal Stock Falls, Then Bounces Back: What’s Going On?

PayPal Holdings Inc (NASDAQ:PYPL) shares are trading higher on Thursday, bouncing back from earlier losses after BofA Securities cut its rating from Buy to Neutral and lowered its price target to $68 from $93. PayPal Holdings stock is showing downward…

Dec 11, 2025
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ:SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. • Sanofi stock is showing upward movement. Why is…